RenovoRx reported second quarter 2026 revenue of $909,000, a 61% sequential increase and 115% year-over-year growth. The company raised its full-year 2026 revenue guidance to $3.75 million–$4.25 million from the previous range of $3.0 million–$4.0 million. RenovoRx ended the quarter with 21 active commercial cancer center customers and announced the first treatment delivered with RenovoCath for sarcoma, expanding beyond pancreatic cancer. The Phase III TIGeR-PaC trial reached full enrollment, with topline data expected in the second half of 2027. Net loss was approximately $2.9 million, and cash reserves stood at $9.5 million as of June 30, 2026. RenovoRx is a life-sciences company developing targeted oncology therapies and commercializing the FDA-cleared RenovoCath drug-delivery device.
